CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04751383
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:36.483560+00:00
Published At: 2026-01-21T00:00:00+00:00
Record Updated At: 2026-01-21
Results Posted At: 2026-01-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High Risk Neuroblastoma", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Refractory Neuroblastoma", "Resectable Osteosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-21"
protocolSection.identificationModule.nctId: "NCT04751383"
protocolSection.identificationModule.officialTitle: "Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-01-21"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.